Business Development

Partnerships and collaborations are a key part of HiFIBiO’s strategy.

We are open to flexible partnership models - out-licensing, development and research collaborations, academic alliances - to maximize the potential of our novel pipeline candidates and to harness the power of our proprietary Drug Intelligence Science (DIS) platform.

Our DIS approach provides a uniquely flexible single cell solution for target, antibody, and biomarker discovery.

Areas of interest

Pipeline

Robust product portfolio focused on immune modulation to treat cancer and autoimmune diseases

  • Out-license of select pipeline assets for global development and commercialization
  • Collaborations to explore novel combinations with HiFiBiO's pipeline assets
  • Collaborations to identify and develop novel therapeutic antibodies

Platform

Proprietary Drug Intelligence Science (DIS™) approach provides a uniquely flexible single cell solution for target, antibody, and biomarker discovery

  • Indication selection and biomarker discovery for advanced patient stratification
  • Discovery and validation of novel therapeutic targets
  • Translational analysis of HiFiBiO's single-cell database

Pipeline

Robust product portfolio focused on immune modulation to treat cancer and autoimmune diseases

  • Out-license of select pipeline assets for global development and commercialization
  • Collaborations to explore novel combinations with HiFiBiO's pipeline assets
  • Collaborations to identify and develop novel therapeutic antibodies

Platform

Proprietary Drug Intelligence Science (DIS™) approach provides a uniquely flexible single cell solution for target, antibody, and biomarker discovery

  • Indication selection and biomarker discovery for advanced patient stratification
  • Discovery and validation of novel therapeutic targets
  • Translational analysis of HiFiBiO's single-cell database
We invite you to get in touch.
Please contact our Business Development Team.

Select Current and Previous Partners

HiFiBiO Therapeutics announced a clinical trial supply agreement with Novartis

Read More

FibroGen, Inc. and HiFiBiO Therapeutics, announced an extension of their partnership

Read More

HiFiBiO Therapeutics announced a publication in Science in collaboration with the Coronavirus Immunotherapy Consortium (CoVIC)

Read More

FibroGen, Inc. and HiFiBiO Therapeutics, announced a partnership covering three HiFiBiO programs.

Read More

Kite and HiFiBio Therapeutics Partner to Discover Novel Targets and Antibodies Against Acute Myeloid Leukemia

Read More

Research Collaboration to Develop Technology for the Treatment of Cancer

Read More

Research Collaboration to Develop Technology for the Treatment of Cancer

Read More

Read our article in Drug Discovery Today for more information on our open-innovation strategy

Read More